Insmed Inc INSM
We take great care to ensure that the data presented and summarized in this overview for INSMED Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INSM
View all-
Darwin Global Management, Ltd. St. Helier, Y919.3MShares$2.36 Billion82.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.6MShares$2.15 Billion0.03% of portfolio
-
Black Rock Inc. New York, NY14.3MShares$1.74 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.2MShares$1.37 Billion0.13% of portfolio
-
Baker Bros. Advisors LP New York, NY7.71MShares$941 Million7.87% of portfolio
-
Capital International Investors Los Angeles, CA7.48MShares$912 Million0.14% of portfolio
-
Jpmorgan Chase & CO New York, NY6.35MShares$775 Million0.04% of portfolio
-
State Street Corp Boston, MA4.28MShares$522 Million0.02% of portfolio
-
Pictet Asset Management Sa Geneva 73, V83.7MShares$451 Million0.09% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.42MShares$418 Million0.28% of portfolio
Latest Institutional Activity in INSM
Top Purchases
Top Sells
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Transactions at INSM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 13
2025
|
Melvin Md Sharoky Director |
BUY
Bona fide gift
|
Indirect |
5,000
+42.2%
|
-
|
|
Aug 13
2025
|
Melvin Md Sharoky Director |
SELL
Bona fide gift
|
Indirect |
15,000
-94.34%
|
-
|
|
Aug 13
2025
|
Melvin Md Sharoky Director |
SELL
Bona fide gift
|
Direct |
6,100
-2.1%
|
-
|
|
Aug 12
2025
|
Melvin Md Sharoky Director |
SELL
Open market or private sale
|
Direct |
10,000
-3.33%
|
$1,210,000
$121.58 P/Share
|
|
Aug 04
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Indirect |
6,830
-0.95%
|
$744,470
$109.8 P/Share
|
|
Aug 04
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
6,830
+2.76%
|
$68,300
$10.85 P/Share
|
|
Aug 04
2025
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,715
-9.49%
|
$949,935
$109.5 P/Share
|
|
Aug 04
2025
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,715
+8.67%
|
$165,585
$19.74 P/Share
|
|
Jul 21
2025
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
58,400
-25.34%
|
$5,956,800
$102.7 P/Share
|
|
Jul 21
2025
|
Sara Bonstein Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,888
+9.45%
|
$1,388,752
$29.62 P/Share
|
|
Jul 15
2025
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
933
-1.39%
|
$95,166
$102.51 P/Share
|
|
Jul 15
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Indirect |
6,830
-0.95%
|
$696,660
$102.56 P/Share
|
|
Jul 15
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
6,830
+2.76%
|
$68,300
$10.85 P/Share
|
|
Jul 11
2025
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
748
-1.1%
|
$71,808
$96.41 P/Share
|
|
Jul 07
2025
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
57,764
-22.99%
|
$5,487,580
$95.93 P/Share
|
|
Jul 07
2025
|
Sara Bonstein Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,888
+8.56%
|
$1,149,312
$24.33 P/Share
|
|
Jul 01
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Indirect |
6,830
-0.95%
|
$669,340
$98.72 P/Share
|
|
Jul 01
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
6,830
+2.76%
|
$68,300
$10.85 P/Share
|
|
Jun 23
2025
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
57,765
-20.46%
|
$5,834,265
$101.93 P/Share
|
|
Jun 23
2025
|
Sara Bonstein Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,889
+13.99%
|
$909,891
$19.35 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 638K shares |
|---|---|
| Exercise of conversion of derivative security | 1.08M shares |
| Open market or private purchase | 3.03K shares |
| Bona fide gift | 17.4K shares |
| Open market or private sale | 1.77M shares |
|---|---|
| Bona fide gift | 33.7K shares |